Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Accumulated Expenses data on file, last reported at $68.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 34.59% year-over-year to $68.1 million; the trailing twelve-month figure through Mar 2026 stood at $68.1 million (down 34.59% YoY), and the FY2025 full-year result was $83.0 million, down 15.74% from the prior year.
• Accumulated Expenses slipped to $68.1 million in Q1 2026, from $83.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $489.1 million in Q4 2022 to a low of $7.7 million in Q1 2022.
• A 5-year average of $163.8 million and a median of $98.5 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 89.01% in 2022 and jumped 5821.06% in 2023, its largest moves.
• Tracing VIR's Accumulated Expenses over 5 years: stood at $489.1 million in 2022, then plunged by 78.69% to $104.2 million in 2023, then declined by 5.47% to $98.5 million in 2024, then declined by 15.74% to $83.0 million in 2025, then declined by 17.95% to $68.1 million in 2026.
• Business Quant data shows VIR's Accumulated Expenses at $68.1 million in Q1 2026, $83.0 million in Q4 2025, and $68.4 million in Q3 2025.